Cervical Cancer Screening Rates Lower Among Mentally Ill


Researchers evaluated cervical cancer screening rates in the severely mentally ill enrolled in California’s Medicaid program and noted lower than average rates in this population.

University of California San Francisco (USCF) researchers evaluated cervical cancer screening rates in the severely mentally ill enrolled in California’s Medicaid program (Medi-Cal) and noted lower than average rates in this population as compared to the general California population.

In a study published in Psychiatric Services, researchers evaluated the records of 31,308 Medi-Cal female recipients from 2010 and 2011, and they found that only 20.2% of the severely mentally ill underwent annual cervical cancer screening compared to 42.3% of California’s general population.

Of these women, white women were less likely to have undergone cervical cancer screening, with Asian women rating the highest. Additionally, they found that severely mentally ill women ages 18 to 27 were 30% less likely to be screened than similarly afflicted women ages 28 to 47.

Most of the women from the study were diagnosed with schizophrenia, followed by major depression, bipolar disorder, anxiety, and other psychiatric diagnoses. Interestingly, researchers did note that those with schizophrenia were the least likely to have undergone screening.

“The women were receiving services in a public health setting, but were not receiving preventive services as often as women in the general population,” said study author Christina Mangurian, MD, associate professor of clinical psychiatry at UCSF. “The results of this very large study indicate that we need to better prioritize cervical cancer screening for these high-risk women with severe mental illnesses.”

Seventy-four percent of patients with evidence of primary care visits were three times more likely to have been screened than those for whom there was no evidence of such health care use.

While the lack of use of healthcare services is one factor likely leading to low screening rates, severely mentally ill women are at a greater risk for developing cervical cancer due to risk factors like smoking and increased numbers of lifetime sexual partners.

Considering strategies are apparently needed to help remove barriers to primary healthcare, researchers suggest using specialty mental health clinics as the “medical home” for women with severe mental illness. Providing “women’s mini-clinics” on site could help alleviate screening disparities.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Related Content